Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00220909 · ClinicalTrials.gov registry record · Phase 4
Lansoprazole Preventing Gastroduodenal Stress Ulcerations
A Phase 4 study, sponsored by Temple University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT00220909 is a Phase 4 study that was terminated before completion, run by Temple University. The registered enrollment target is 40 participants.
The verdict
NCT00220909, a Phase 4 study, was terminated before completion, sponsored by Temple University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine whether lansoprazole, administered intravenously, can protect patients undergoing cardiac surgery from the development of and/or progression of previously undetected acid/peptic disorders (erosive esophagitis, gastric ulcer, duodenal ulcer, diffuse gastritis, duodenitis) as measured by the Lanza score and LA classification for esophageal injury. The secondary objectives of this study are: 1. To determine if intravenous lansoprazole protects against the development of clinically important gastrointestinal bleeding in this population (overt bleeding or requiring blood transfusion). 2. To determine if intravenous lansoprazole maintains the intragastric pH above that for placebo throughout the study period.
Interventions
- DRUG Lansoprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2005-09 |
| Est. Completion | 2006-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00220909
The ClinicalTrials.gov registry entry for NCT00220909 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Temple University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lansoprazole is the first listed.
NCT00220909 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00220909 about?
NCT00220909 is a clinical study titled "Lansoprazole Preventing Gastroduodenal Stress Ulcerations". The primary objective of this study is to determine whether lansoprazole, administered intravenously, can protect patients undergoing cardiac surgery from the development of and/or progression of previously undetected acid/peptic disorders (erosive esophagitis, gastric ulcer, duodenal ulcer, diffuse...
What is the current status of trial NCT00220909?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2005-09. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00220909?
The interventions under investigation include: Lansoprazole (DRUG).
Who is sponsoring clinical trial NCT00220909?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.